Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 3Recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Neoplasms, Plasma Cell 14Recurrence 12Leukemia 12Vomiting 11Lymphoma, Extranodal NK-T-Cell 11Lymphoma 11Neoplasms 9Nausea 6Lymphoma, Mantle-Cell 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Paraproteinemias 3Lymphoma, T-Cell, Peripheral 3Lymphoma, B-Cell, Marginal Zone 3Lymphohistiocytosis, Hemophagocytic 3Lung Neoplasms 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Diseases 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Burkitt Lymphoma 3Breast Neoplasms 3Blood Protein Disorders 3Renal Insufficiency 2Postoperative Nausea and Vomiting 2Polycystic Ovary Syndrome 2Peripheral Nervous System Diseases 2

Interventions

Cyclophosphamide 5fludarabine 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Gemcitabine 3fludarabine phosphate 2endostar protein 2Melphalan 2Etoposide 2Doxorubicin 2Cisplatin 2Alemtuzumab 2thymoglobulin 1spartalizumab 1selinexor 1pembrolizumab 1Vindesine 1Vincristine 1Sensitivity and Specificity 1Rituximab 1Prednisone 1Prednisolone 1Methylprednisolone 1Interleukin-2 1Flavin-Adenine Dinucleotide 1Epirubicin 1Endostatins 1Drug Therapy 1Dexamethasone 1Cytarabine 1Clinical Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, T-Cell × Dexamethasone × Clear all
NCT05821192 2023-04-20

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

The First Hospital of Jilin University

Phase NA Unknown
34 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡